Through rigorous research, education, and global collaboration, SIDHE seeks to break down barriers, advance understanding, ...

To fully harness and embody their Jupiterian strengths and wisdom, exploring the best crystals for Sagittarius can be ...

Sage Therapeutics (SAGE) stock falls as Huntington's Disease candidate dalzanemdor fails in Phase 2 trial. Read more here.

Sage Therapeutics ends dalzanemdor development after Phase 2 trials for Huntington's and Alzheimer's fail to meet primary ...

“Today, the user manually creates the symbols, the footprints, the 3D models ... “If we can add support for PCB schematics as a modality, it could extract knowledge from existing schematic graphics,” ...

The Phase II DIMENSION study of Sage's dalzanemdor failed to meet its primary and secondary endpoints for treating Huntington ...

After previously failing studies in Parkinson’s and Alzheimer’s, dalzanemdor’s latest stumble in Huntington’s disease has ...

TD Cowen lowered the firm’s price target on Sage Therapeutics (SAGE) to $9 from $10 and keeps a Hold rating on the shares. The firm noted they ...

Sage Therapeutics' run of bad news has continued with a failed phase 2 trial of dalzanemdor as a treatment for cognitive ...

Sage Therapeutics (SAGE) announced topline results from the Phase 2 DIMENSION Study of dalzanemdor, or SAGE-718, in participants with cognitive ...

Sage Therapeutics’ SAGE phase II study evaluating its neuropsychiatric candidate, dalzanemdor (SAGE-718), for treating ...

Changes in thinking, learning, and memory are some of the most distressing and impactful in Huntington’s disease. Sage ...